Under Q2 mjuklanserades bolagets nikotinpåsar i utvalda butiker och inom läkemedelsutveckling är Emp...
Redeye expects the first sales of Sedaconda in the UK by year-end, following today’s full UK approva...
Provides updated development plan at investor meeting Detailed path forward for different rights iss...
Redeye is pleased with Arise’s Q3 production figure of 59.
Redeye comments on Mestro's news regarding its partnership with SBC, one of Sweden's largest propert...
Redeye endorses today’s news that Egetis has filed a marketing authorization application (“MAA”) for...
On September 21, Carasent announced that it would initiate a share buyback program and deliver a spe...
(Correction refers to the link to the analysis) Provides updated development plan at investor meetin...
Duell’s Q4 results were largely in line with the previously released preliminary figures.
Positiva data Första resultaten från fas 2b-studien med pudafensine inom organisk erektil dysfunktio...
Redeye is encouraged to learn that Initiator Pharma’s most advanced candidate, pudafensine, demonstr...
A novel, environmentally beneficial approach to a USD 20bn problem A competitive edge in a USD 400m ...
Redeye is encouraged to learn that Moberg Pharma has completed the enrollment to the Phase 3 study f...
Redeye comments on Medivir's new early positive data from all patients in the study of fostrox + Len...
Incap downgraded its 2023 guidance on 5 October due to weaker-than-expected orders from its main cus...
Redeye is encouraged by the announcement that Nanexa’s clinical phase I trial with NEX-20 (NEX-20-01...
Another solid quarter awaits after the turnaround in Q4'22 Limited revisions - we forecast a resilie...
Reinitiating coverage, fair value range SEK 14-38 Q2: accelerating org.
Solteq’s near-term challenges continue and operative profitability is looking weak this year.
E&P in wins tender in collaboration with close partners No impact on financial guidance We currentl...
